Article
A novel fibroblast growth factor-1 ligand with reduced heparin binding protects the heart against ischemia-reperfusion injury in the presence of heparin co-administration.
Cardiovascular research - 1 Nov 2017
Huang Chahua, Liu Yang, Beenken Andrew, Jiang Lin, Gao Xiang, Huang Zhifeng, Hsu Anna, Gross Garrett J, Wang Yi-Gang, Mohammadi Moosa, Schultz Jo El J
Abstract excerpt
AIMS: Fibroblast growth factor 1 (FGF1), a heparin/heparan sulfate-binding growth factor, is a potent cardioprotective agent against myocardial infarction (MI). The impact of heparin, the standard of care for MI patients entering the emergency room, on cardioprotective effects of FGF1 is unknown, however. METHODS AND RESULTS: To address this, a rat model of MI was employed to compare cardioprotective potentials...
Topics
Join the communities discussing this publication.